In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine.
A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100% of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t(1/2) of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.
Pao
Li-Heng
LH
Department of Research, Development and Continuing Education, National Defense Medical Center, 161 Minchuan East Road, Sec. 6, Taipei, Taiwan, R.O.C.
Hsiong
Cheng-Huei
CH
Hu
Oliver Yoa-Pu
OY
Wang
Jhi-Jung
JJ
Ho
Shung-Tai
ST
D000701:Analgesics, Opioid / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D019540:Area Under Curve; D004285:Dogs; D004912:Erythrocytes / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D008297:Male; D009266:Nalbuphine / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D009292:Narcotic Antagonists / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D010949:Plasma / Q000737:chemistry / Q000378:metabolism; D011355:Prodrugs / Q000032:analysis / Q000493:pharmacokinetics*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012715:Sesame Oil; D013045:Species Specificity
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D011355:Prodrugs; C420448:sebacoyl dinalbuphine ester; D012715:Sesame Oil; D009266:Nalbuphine